NCT01371617

A Phase 2 Study With IPI-926 in Patients With Myelofibrosis

A Phase 2 Study of IPI-926 in Patients With Myelofibrosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Infinity Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety and efficacy of IPI-926 in patients with myelofibrosis (MF) (primary myelofibrosis \[PMF\], post-polycythemia vera myelofibrosis \[post-PV MF\], or post-essential thrombocythemia myelofibrosis \[post-ET MF\]).

Conditions

• Primary Myelofibrosis
• Fibrosis, Bone Marrow

Interventions

Type	Name	Description
DRUG	IPI-926	Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF

Timeline

• Start date: 2011-10-01
• Primary completion: 2012-08-01
• Completion: 2012-08-01
• First posted: 2011-06-13
• Last updated: 2012-11-15

Locations

3 sites across 1 country: United States